TIR

Insulet’s Randomized Controlled Trial (OP5-003) Demonstrates Omnipod® 5 Automated Insulin Delivery System is Superior to Pump Therapy

Retrieved on: 
Friday, March 8, 2024

The OP5-003 Trial results were presented at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in Florence, Italy.

Key Points: 
  • The OP5-003 Trial results were presented at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in Florence, Italy.
  • "Omnipod 5 continues to demonstrate impressive clinical outcomes for people with type 1 diabetes,” said Professor Renard.
  • The control group (n=62) continued to use their usual insulin pump with a Dexcom G6 CGM, while the intervention group (n=132) used Omnipod 5 with Dexcom G6.
  • In conclusion, this multi-national, RCT data demonstrates the superiority of the Omnipod 5 AID System compared to standard pump therapy with CGM and indicates that it should be offered as a first-line therapy for adults with type 1 diabetes.

New real-world data shows MiniMed™ 780G system sustains strong global performance, exceeding international targets for diabetes management

Retrieved on: 
Saturday, March 9, 2024

DUBLIN and FLORENCE, Italy, March 9, 2024 /PRNewswire/ -- Medtronic plc. (NYSE: MDT), a global leader in healthcare technology, today shared a robust set of new clinical and real-world evidence on the MiniMed™ 780G system from around the world including the largest set of data from early users in the United States. The data was presented at the 17th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD) in Florence, Italy. These results build on the 3-year data published in Diabetes Technology & Therapeutics showing over 100,000 real-world users achieving a Time in Range (TIR) of 78% with the use of recommended optimal settings, outperforming international targets of 70% TIR.

Key Points: 
  • The data was presented at the 17th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD) in Florence, Italy.
  • These results build on the 3-year data published in Diabetes Technology & Therapeutics showing over 100,000 real-world users achieving a Time in Range (TIR) of 78% with the use of recommended optimal settings, outperforming international targets of 70% TIR.
  • In an oral presentation, Dr. James Thrasher, MD, Founder, Arkansas Diabetes and Endocrinology Center, shared data on early real-world users with type 1 diabetes of the MiniMed™ 780G system in the U.S. (n=7,499).
  • This data reinforces that the determinant of choice for AID systems should be first and foremost the power of the algorithm."

eddii, the Gamified Real-Time Diabetes Management App, Launches Nationwide

Retrieved on: 
Wednesday, December 20, 2023

NEW YORK, Dec. 20, 2023 /PRNewswire-PRWeb/ -- Today, eddii marks a milestone with the announcement of its nationwide launch, bringing a gamified approach to diabetes management to all those living with the condition across the country, who want to improve their health in more enjoyable ways. More than just an app, eddii functions as a smart, virtual health companion, delivering real-time feedback, unwavering support, and in-app rewards as a testament to healthy behavior.

Key Points: 
  • Now available nationwide, eddii gamifies real-time glucose data from Dexcom CGMs, making diabetes management a whole lot more fun
    NEW YORK, Dec. 20, 2023 /PRNewswire-PRWeb/ -- Today, eddii marks a milestone with the announcement of its nationwide launch, bringing a gamified approach to diabetes management to all those living with the condition across the country, who want to improve their health in more enjoyable ways.
  • eddii is gearing up to launch even more features as early as next year," said Farhaneh Ahmadi, PhD, eddii's CEO.
  • While initially prioritizing the well-being of children with diabetes and their families, eddii has set its sights on expanding into the adult market in the very near future.
  • eddii is on a mission to enable access to diabetes care in every corner of the US, hence an initial focus on rural areas.

CellOrigin announced treatment of the first patient with CAR-M in China and reported the second generation of CAR-M for solid tumors

Retrieved on: 
Wednesday, December 20, 2023

The successful completion of the first patient dosing of SY001  demonstrates the advanced technology of the company's R&D platform and the maturity of the CMC platform.

Key Points: 
  • The successful completion of the first patient dosing of SY001  demonstrates the advanced technology of the company's R&D platform and the maturity of the CMC platform.
  • Only 2 grade 3 adverse events occurred; Common grade 1 - 2 adverse events included fever, elevated C-reactive protein, etc.
  • Based on M-CAR, a functionally enhanced second generation CAR-iMAC has been developed to enhance the effectiveness of the therapy for solid tumors.
  • The mechanism of antigen-dependent activation and polarization of the second generation CAR-iMAC and the mechanisms of solid tumor cell killing were also revealed.

eddii, a gamified diabetes app, is now available in sixteen states across the United States

Retrieved on: 
Tuesday, December 5, 2023

NEW YORK, Dec. 5, 2023 /PRNewswire-PRWeb/ -- eddii, a new diabetes management interface that gamifies real-time glucose data, is pleased to announce its launch in the states of Iowa, South Dakota, North Dakota, Minnesota, Wisconsin, Michigan, Ohio, Indiana, Illinois, and Missouri. By launching in these additional states, eddii plans to increase access to diabetes care for families living in rural areas of the country.

Key Points: 
  • By launching in these additional states, eddii plans to increase access to diabetes care for families living in rural areas of the country.
  • eddii is focusing on supporting children living with diabetes and their families, with plans to expand into the adult market very soon.
  • Earlier this year, eddii also launched in the states of Oklahoma, Texas, Nebraska, Louisiana, Arkansas, and Kansas, with more state releases on the horizon.
  • "We strive to serve families in all parts of the United States who would like easier access to diabetes care.

eddii, a gamified diabetes app, has now launched in the states of Arkansas, Louisiana, Nebraska, and Kansas

Retrieved on: 
Monday, November 13, 2023

LITTLE ROCK, Ark., Nov. 13, 2023 /PRNewswire-PRWeb/ -- eddii, a new diabetes management interface that gamifies real-time glucose data, is pleased to announce its launch in the states of Arkansas, Louisiana, Nebraska and Kansas, as it proceeds with its plans to expand nationwide.

Key Points: 
  • By launching in these select states in the South and Midwest of the United States, eddii plans to increase access to diabetes care for families living in rural areas of the country.
  • eddii is focusing on children living with diabetes and their families, with plans to expand into the adult market very soon.
  • With eddii, children and their families take managing diabetes to a different level, motivating them to stick to healthy routines.
  • That way, parents can have a reliable interface at the tip of their hands to manage their child's diabetes."

eddii, a gamified diabetes management app, is now live in Texas

Retrieved on: 
Thursday, October 19, 2023

DALLAS, Oct. 19, 2023 /PRNewswire-PRWeb/ -- eddii, a new diabetes management interface that gamifies real-time glucose data, is pleased to announce its launch in the state of Texas, as it proceeds with its plans to expand nationwide.

Key Points: 
  • "There are more than 21,000 children living with diabetes in the state of Texas, one of the largest populations of children with diabetes in the US.
  • eddii is focusing on children living with diabetes and their families, with plans to expand into the adult market very soon.
  • "There are more than 21,000 children living with diabetes in the state of Texas, one of the largest populations of children with diabetes in the US.
  • With eddii, children and their families take managing diabetes to a different level, motivating them to stick to healthy routines.

eddii, a gamified diabetes management app, launches in Oklahoma

Retrieved on: 
Wednesday, September 20, 2023

TULSA, Okla., Sept. 20, 2023 /PRNewswire-PRWeb/ -- eddii, a new diabetes management interface that gamifies real-time glucose data, is pleased to announce its launch in the state of Oklahoma, with plans to expand its program nationwide later this year.

Key Points: 
  • "We are thrilled to be bringing people in the state of Oklahoma a new way to manage type-1 diabetes (T1D)," said Farhaneh Ahmadi, PhD, eddii's CEO.
  • eddii is focusing on children living with diabetes and their families, with plans to expand into the adult market very soon.
  • "We are thrilled to be bringing people in the state of Oklahoma a new way to manage type-1 diabetes (T1D)," said Farhaneh Ahmadi, PhD, eddii's CEO.
  • "The T1D community and families in Oklahoma have enthusiastically supported eddii throughout, sharing their experiences and participating in the development of eddii.

Time in Range Coalition launches vast resource site for time in range education

Retrieved on: 
Wednesday, September 6, 2023

SAN FRANCISCO, Sept. 6, 2023 /PRNewswire/ -- The Time in Range Coalition has launched timeinrange.org—a vibrant new website and the first of its kind, created by people with diabetes, international diabetes experts, and key industry leaders. It focuses on the exciting, useful, and quickly growing diabetes management metric time in range and features resources for people with diabetes, healthcare professionals, and the entire diabetes community. The site meets an unmet need in the diabetes ecosystem by providing a "one-stop shop" solely focused on time in range—and creates an accessible online space where people with diabetes can feel empowered in their diabetes management.

Key Points: 
  • The Time in Range Coalition has launched timeinrange.org, a website dedicated to providing education and resources about the daily diabetes management metric to people living with diabetes, healthcare professionals, and more.
  • Research has shown that utilizing time in range to make treatment decisions can lower A1C, decrease diabetes complications, and seriously improve people with diabetes' quality of life.
  • It's a vitally important diabetes metric that has been embraced by people with diabetes and clinicians in the global diabetes ecosystem.
  • Timeinrange.org is a project that has been years in the making and aims to be the new household name in time in range education.

Hua Medicine Announces 2023 Interim Results

Retrieved on: 
Friday, August 25, 2023

Hua Medicine (the "Company", HKEx: 2552) today announces the unaudited consolidated results of the Company and its subsidiaries for the six months ended June 30, 2023 (the "Reporting Period").

Key Points: 
  • Hua Medicine (the "Company", HKEx: 2552) today announces the unaudited consolidated results of the Company and its subsidiaries for the six months ended June 30, 2023 (the "Reporting Period").
  • Dr. Li Chen, the founder and CEO of Hua Medicine, said, "the first half of 2023 was a critical stage for Hua Medicine to begin commercialization.
  • The revenue of Hua Medicine for the first half of 2023 was RMB70.3 million, which was an increase of approximately 299.6% comparing to the second half of 2022.
  • This article contains the statements regarding the future expectations, plans and prospects for Hua Medicine and the investigational product.